[Successful treatment of an infant with fulminant hepatitis by factor VII concentrate].
A 2-month-old boy was admitted to our hospital because of poor sucking and jaundice. There were no abnormalities during the whole period of pregnancy and at birth. His mother was a HBeAb positive HBsAg carrier, but prophylactic maneuver such as anti-HB immunoglobulin and HB vaccine was not performed on him at birth. Physical examination on admission revealed mild disturbance of consciousness. The laboratory findings showed marked increments of serum bilirubin, GOT, GPT, and NH3, and prolongation of prothrombin time, activated partial thromboplastin time and hepaplastin test. Thus, he was diagnosed as fulminant hepatitis and treated with exchange transfusion once or twice a day. Biochemical data improved gradually, but hypocoagulable states remained unchanged. At that time we decided to use Factor VII concentrate, because we found that, among several coagulation factors, factor VII activity decreased most rapidly after exchange transfusion. The alternate therapy of exchange transfusion and Factor VII concentrate improved his coagulation abnormality without any side effects. Our experience suggests that the combination therapy of exchange transfusion and Factor VII concentrate may be useful for management of fulminant hepatitis, particularly for uncontrollable coagulopathy.
Kawada
Y
Y
Shiiki
M
M
Miyagawa
T
T
Kajiwara
Y
Y
Shirahata
A
A
Yamagishi
M
M
D000208:Acute Disease; D001777:Blood Coagulation / Q000187:drug effects; D003131:Combined Modality Therapy; D005078:Exchange Transfusion, Whole Blood; D005167:Factor VII / Q000627:therapeutic use*; D006509:Hepatitis B / Q000097:blood / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male
D005167:Factor VII